We are pleased to share some exciting news. PerkinElmer has entered into a definitive agreement to acquire Caliper Life Sciences. Our goal upon close is to bring together key technologies to deliver unmatched imaging, detection and sample preparation solutions, services and expertise that provide you with greater insights and critical knowledge to help you drive improved results and better decisions, faster. The combination of PerkinElmer and Caliper Life Sciences will provide:
Hospira Inc. looks to generic versions of biologic-style drugs and international expansion for future growth, F. Michael Ball, chief executive of the generic-injectable-drug maker, said during an investor conference Wednesday. "There's not a big need to change strategy here," Ball said. "There's simply the need to globalize it." He said Hospira can do this by getting existing products approved in other countries and through acquisitions in emerging markets, which present a $5 bil...
According to Silicon Valley/San Jose Business Journal a study by The Boyd Company, Inc. (pdf) which examined 55 locations in North and Latin America to compare device manufacturing costs. The San Jose/Palo Alto area topped the list, with total operating costs at more than $30 million. It had the highest overall costs in labor, power, land, taxes and shipping for an average 325-employee production plant.
For the first time in its history, Medicare will soon track spending on millions of individual beneficiaries, reward hospitals that hold down costs and penalize those whose patients prove most expensive. The administration plans to establish “Medicare spending per beneficiary” as a new measure of hospital performance, just like the mortality rate for heart attack patients and the infection rate for surgery patients. This Sunday on “Face the Nation,” Rep. Eric Cantor told host Harry Smith that ...
Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration (FDA) has approved Solesta as a treatment for fecal (bowel) incontinence in adult patients who have failed conservative therapy such as dietary control. The FDA approval was given on the basis of the positive results from a clinical trial involving 206 patients. In the primary study, most patients received two trea...
Robert F Friel letter to shareholdersTuesday, 12 August 2008 00:25
Hospira Inc. looks to generic versions of biologic-style drugs and international expansionSaturday, 28 May 2011 17:03
San Jose/Palo Alto most expensive for Medical Device ProductionTuesday, 31 May 2011 03:27
GOP’s Medicare voucher planTuesday, 31 May 2011 15:44
FDA Approves Solesta;Tuesday, 31 May 2011 18:37
|Ian Read, Chairman and Chief Executive Officer, stated|
Ian Read, Pfizer Chairman and Chief Executive Officer, stated, “Overall, 2011 was a year of setting new direction and focus for Pfizer. I am pleased with our 2011 financial performance, which was achieved in the face of a challenging global market and product losses of exclusivity of approximately $5 billion. We also made significant progress regarding capital allocation for the benefit of our shareholders during 2011.” “In 2011, we advanced our pipeline and improved the rigor and productivity of our research and development (R&D) efforts, while also changing the culture within the R&D organization to be more accountable and results-driven. With the steady cadence of new product launches, marketing submissions and approvals, and positive late-stage clinical data presentations, we are clearly seeing the benefits of our investments and new approach. Prevnar/Prevenar 13 for adults, tofacitinib, Xalkori, Inlyta (axitinib) and Eliquis are well positioned to be important new product opportunities that may enhance the performance of our business. Additionally, we have a next wave of compounds that have shown promise in early and mid-stage studies, and we look forward to progressing them through the pipeline. Each of these compounds represents a potential valuable, new treatment option for patients.”
|Amgen: Short Profile|
Amgen is world’s largest independent biotechnology medicines company. Amgen is in the business of discovering, developing, manufacturing and marketing medicines for grievous illnesses. Amgen focuses solely on human therapeutics and concentrate on innovating novel medicines based on advances in cellular and molecular biology. Amgen's mission is to serve patients. They were incorporated in 1980 and organized as a Delaware corporation in 1987. Amgen's public website is www.amgen.com.
As of December 31, 2010, we had 17,400 staff members worldwide. Approximately 6,700 of Amgen's staff members work in their research and development (“R&D”) function, approximately 4,600 work in manufacturing, approximately 4,200 work in it's commercial operations and the rest are in general and administrative functions.